Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

NCT02047214 is registered in ClinicalTrials.gov with Cortice Biosciences, Inc. as lead sponsor.

NCT NCT02047214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02047214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen
Lead sponsor
Cortice Biosciences, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2014
Completion date
December 31, 2015
Enrollment
17 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme